Brief: Celyad Oncology Announces Voluntary Pause Of CYAD-101-002 Phase 1b Trial
28/02/2022 07:37
Feb 28 (Reuters) - Celyad Oncology SA CYAD.BR :
* ANNOUNCES VOLUNTARY PAUSE OF CYAD-101-002 PHASE 1B TRIAL
* LASTLY, WE ANTICIPATE NO IMPACT ON OUR SHRNA-BASED
CANDIDATES,
INCLUDING CYAD-211 CURRENTLY UNDER INVESTIGATION FOR TREATMENT
OF MULTIPLE MYELOMA
* THE COMPANY HAS RECEIVED REPORTS OF TWO FATALITIES THAT
PRESENTED WITH SIMILAR PULMONARY FINDINGS
* COMPANY IS CURRENTLY INVESTIGATING THESE REPORTS AND
EVALUATING
ANY SIMILAR EVENTS IN ADDITIONAL PATIENTS TREATED ON STUDY
* THE COMPANY HAS DECIDED TO VOLUNTARILY PAUSE DOSING AND
ENROLLMENT OF PATIENTS IN THE CYAD-101-002 TRIAL IN ORDER TO
INVESTIGATE THESE EVENTS
* COMPANY IS INFORMING REGULATORY AGENCIES, WHICH MAY
REQUIRE
ADDITIONAL ACTIONS OF COMPANY
* COMPANY EXPECTS TO PROVIDE ADDITIONAL UPDATES ON TRIAL IN
NEAR
FUTURE
Source text for Eikon: ID:nGNXb2GNdl
Further company coverage: CYAD.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))